The Food and Drug Administration has asked Dendreon Corp.  to stop using some promotional materials for Provenge, saying they are “false or misleading” because they omit or minimize the prostate-cancer drug’s risks and overstate its effectiveness.

Provenge, which was approved by the agency in late April, is seen as the first in a new class of cancer-fighting drugs that use a patient’s cells to stimulate the body’s immune system to fight cancer. Get the full story »